Donor-derived mitochondrial DNA variant peptides elicit allo-specific immune response in transplant patients

Argit Marishta^{1,2}, Yanqin Yang^{1,2}, Xiaomeng Hu³, Moon Kyoo Jang^{1,2}, Karen Cuttin^{1,2}, Annette M. Jackson^{5,#}, Helen Luikart⁴, Tobias Deuse³, Kiran K. Khush⁴, Sonja Schrepfer³, Sean Agbor-Enoh^{1,2,5}, Hannah Valantine^{1,2}

¹ Laboratory of Transplantation Genomics, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.

² Genomic Research Alliance for Transplantation (GRAfT), Bethesda, Maryland, USA.

³ Department of Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California San Francisco (UCSF), San Francisco, California, USA

[#]Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA

⁴ Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA

⁵ Pulmonary and Critical Care Medicine, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Corresponding Author: Hannah Valantine, hannah.valantine@nih.gov and Sean Agbor-Enoh, sean.agbor-enoh@nih.gov

Abstract

In stem cell transplant, mitochondrial DNA (mtDNA) nonsynonymous single nucleotide variants (SNVs) between donor and recipient (D-R) trigger alloimmune responses and transplant rejection. Whether similar alloimmune responses occurs in solid-organ transplantation remains unknown, particularly with the presence of human leukocyte antigen mismatches. This study characterized mtDNA SNVs between D-R of 163 human lung transplant pairs, and then, post-transplantation, assessed alloimmune responses against donor-derived mitochondrial peptides using ELISpot to measure interferon gamma (IFN γ) release from recipient's monocytes. We identified a median of 6 nonsynonymous mtDNA SNVs (Interquartile Range = 4 – 9) per D-R pair. SNVs were predominantly located at *MT-CYB*, *MT-ATP6*, and *MT-ND3* genes. The number of SNVs was higher in D-R race non-concordant pairs than in race-concordant pairs. Donor-derived mitochondrial peptides triggered a 19.8-fold higher IFN γ release compared to recipient-derived peptide. These findings were validated in heart transplantation and show that donor-derived mitochondrial peptides trigger allo-specific immune responses after transplantation.

Introduction

Alloimmune response remains a major drive for development of acute and chronic rejection (1).

Traditionally, the alloimmune response is thought to be primarily driven by mismatched human leukocyte antigens (HLA). However, acute rejection has been reported in the absence of HLA-directed alloimmune responses(2-5). Mitochondrial-derived protein mismatch between transplant donor and recipient potentially could contribute to alloimmune response. For example, in a stem-cell transplant, where immunologically dominant MHC and other nuclear antigens are matched between the stem cells and recipient, mismatched mitochondria between the stem cells trigger allo-specific immunity (6, 7). Deuse and collaborators utilized somatic cell nuclear transfer to create stem cells with the same nuclear DNA, but with different mtDNA as the host mice. Upon transplantation, host mice developed allo-specific immune responses directed against mitochondrial antigenic mismatch and rejected the stem cells (6). In solid-organ transplantation, particularly heart and lung transplantation, antigenic matching is not performed. Therefore, alloreactivity of mitochondrial antigenic mismatches between donor and recipient deserves investigation, because such mismatches could trigger chronic rejection.

Transplant recipients of non-European ancestry, particularly Black/African American, have higher acute rejection rates across several organ transplant types (8, 9). The reason for higher rejection rates in Black/African American organ transplant recipients is not fully known, and is often attributed to multiple complex immunobiological and socioeconomic factors (10). For example, African American transplant recipients have greater donor HLA variance compared to recipients of European descent (10, 11). Furthermore, the variance of mitochondrial-derived proteins among different human population groups is well established (12). We reasoned that the variability between the donor- and recipient-derived mitochondrial proteins could provide an explanation for higher rejection rates in Black/African American heart transplant recipients. A new understanding of alloimmune response drivers could offer new mechanisms for the prevention of acute and chronic rejection(3, 13, 14). An essential first step towards

that understanding would be to characterize mtDNA variability between the donor- and recipient, setting up the rationale for further clinical studies.

Mitochondrial DNA (mtDNA) differs in size and shape from the nuclear genome and is evolutionarily similar to bacterial DNA (15, 16). mtDNA encodes 13 proteins that, in collaboration with other nuclear-encoded proteins, maintain oxidative phosphorylation (OXPHOS) and produce ATP (15, 17). In addition, mtDNA and other mitochondria damage-associated molecular patterns (DAMPs) trigger higher inflammation than nuclear DNA once released in circulation (15). In a transplant setting with genetic mixing, leakage of allograft mitochondrial peptides and DNA possibly sets the stage for inflammation and allo-immune activation (18-21). Therefore, we hypothesize that nonsynonymous mtDNA SNVs result in donor-derived peptides that trigger allo-specific immunity in solid-organ transplant recipients.

This study had three objectives. First, characterize mtDNA SNVs between lung transplant recipients and donors; second, determine if donor-derived peptides with nonsynonymous SNVs trigger allo-specific immune responses in vitro; and third, validate the allo-specific immune response by replicating the analysis in heart transplant patients.

Methods

Study design

Patients from two prospective cohort studies, Genomics Transplant Dynamics (GTD: NCT01985412) and Genomics Research Alliance for Transplantation (GRAFT; NCT02423070), were included. GTD is a single center study (Stanford Healthcare) and GRAFT is a multicenter study consisting of five centers in the Washington DC area (INOVA Fairfax Hospital, Medstar Washington Hospital Center, Virginia Commonwealth University Hospital, University of Maryland Medical Center, and Johns Hopkins Hospital). Both studies have similar study designs (22-24). The primary analysis for this study included 163 lung transplant patients, all enrolled while they were on the transplant waitlist. A pre-transplant blood sample was collected from each subject and their transplant donor to isolate mtDNA, complete sequencing, and characterize SNVs. Patients without pre-transplant blood samples were excluded. mtDNA SNVs identified by high-throughput sequencing were validated by two other platforms – digital droplet PCR and targeted sequencing (25). Approximately one-year post-transplantation, we collected recipient peripheral blood mononuclear cells (PBMCs) and used Elispot to determine allo-specific immune responses triggered by donor-derived peptides. To test allo-specific immune responses triggered by donor-derived mitochondrial peptides in other solid-organ transplants, we repeated the analyses in 19 heart transplant recipients. This study was approved by the institutional review boards of the recruiting centers and the National Heart, Lung and Blood Institute. The study design is depicted in Figure 1.

Figure 1

Figure 1. Study design.

mtDNA of 163 lung transplant recipients and their organ donors were sequenced. Sequencing reads were analyzed and SNVs for each D-R pair were counted. Peptides at the mitochondria protein coding region differing at one amino acid between the donor and recipient were synthesized. Then, Elispot assay was used to measure the release of IFN γ from peripheral mononuclear blood cells post-transplantation when stimulated with the constructed peptides.

mtDNA isolation, library construction and sequencing.

Total DNA, which contains nuclear and mitochondrial DNA, was extracted from whole blood (DNeasy Blood and Tissue kit, Qiagen, Cat No. 69506). Mitochondrial DNA was enriched by step-wise depletion of nuclear DNA. The first step involved incubation of total DNA with proteinA-MBD2-Fc mixture (NEBNext Microbiome DNA Enrichment Kit, New England BioLabs, Microbial enrichment kit, New England Biolabs, Cat No. E2612L), which binds and depletes methylated nuclear DNA fragments. This was followed by exonuclease treatment to digest and deplete linear nuclear DNA strands over circular mtDNA. Quantitative PCR was performed after each step using primers specific to nDNA and mtDNA. mtDNA enrichment efficiency was computed as a ratio of mtDNA-to-nDNA. The enriched mtDNA was then amplified by multiple displacement technology (MDA) using specific primers (REPLI-g Mitochondrial DNA kit, Qiagen, Cat No. 151023), followed by library construction (Nextera XT Sample Prep Kit, Illumina, Cat No. 15032354) and sequencing (pair-end, 50bp) on Illumina HiSeq3000.

Characterization of SNVs

Sequencing reads were trimmed using Trimmomatic (26) and aligned to the revised Cambridge Reference Sequence (rCRS, accession number: NC_012920) (27) using BWA (v0.7.17) (28). Properly aligned paired-end reads were retrieved and analyzed using samtools (v1.4)(29). SNVs between each D-R pair were called with mpileup2snp in VarScan (v.2.4.3) (30), using the following parameters: minimum-coverage 500, minimum-reads 10, minimum-average-quality 26, minimum-variant-frequency 0.02, minimum-frequency-for-homoplasmy 0.95. The frequency of each single nucleotide variant was computed separately for donor and recipient. Variants were annotated using ANNOVAR database (31) and nonsynonymous SNPs were inputted into UniProtKB database (32) to retrieve peptide sequences.

SNV was present if a D-R pair showed a difference in their variant frequencies of at least 5%. Estimate error rate of sequencing and SNVs calls was 0.1%, so an arbitrary threshold of 5% was selected to reduce erroneous SNVs calls. SNVs were defined as homoplasmic SNV if the variant frequency difference

between D-R was greater than 90% or heteroplasmic SNV if the frequency difference was between 5% and 90%.

Peptide synthesis, PBMC reactivation, Elispot

mtDNA sequences were translated into protein sequences. Nonsynonymous SNVs were defined as single nucleotide variants that lead to mismatched amino acids between D-R. A subset of patients (n=10 patients) were randomly selected. We then constructed and commercially synthesized two 20-mer peptides from each nonsynonymous SNVs position; one with donor amino acid and one with recipient amino acid. Both peptides contained identical amino acid sequences except for a single amino acid difference. One-year post-transplantation, we collected whole blood and isolated PBMCs. We used Elispot to assay for interferon gamma (IFN γ) release as described elsewhere by Deuse and colleagues (25). The number of IFN γ -spots were compared for donor-derived and recipient-derived mt peptides.

Validation study in heart transplantation

To demonstrate that nonsynonymous donor-derived mtDNA mismatch triggers allo-immunity in other solid-organ transplants, we repeated the analysis in 19 heart D-R pairs. For these patients, we obtained and sequenced donor and recipient pre-transplant mtDNA, characterized the number of SNVs. In a randomly selected subset of patients (n=4), we identified nonsynonymous SNVs, constructed donor-derived and recipient-derived 20-mer peptides and performed Elispot assays. All samples were similarly processed and analyzed as the lung transplant samples.

Statistical tests

To compare the number of SNVs between demographic groups, we focused the analysis on race and age, given its known association with mtDNA variance (12), and sex, given mitochondria's maternal inheritance. We employed the non-parametric Wilcoxon signed-rank test to compare the number of SNVs measures between groups, given that the skewness (> 1.05) of the number of SNVs was beyond the limit

of normality. Statistical analyses were performed in JMP13 software. For all comparison tests we report median and interquartile range (IQR).

Self-reported sex, age and race were then examined. Each D-R pair was characterized as sex/race concordant (donor and recipient reported the same sex/race) or sex/race non-concordant (donor and recipient reported different sex/race). For age, we used the median age of donors (35 years), and recipients (50 years) to split the cohort into four groups: young donor – young recipient, old donor – young recipient, old donor – old recipient, and young donor – old recipient.

Next, we examined the frequency of SNVs across the different mitochondria genes. To account for the differences in gene length between each of the mitochondria genes, we normalized the analysis for gene length using the following formula: [(gene SNV #) / (mitochondria gene length)] x (16,569 bp mtDNA genome)

Results

Description of study cohort

The 163 lung transplant recipients were 51 ± 15 years old at transplantation, 15 years older than their donors (36 ± 14). Half of recipients and two thirds of the donors were males. Among recipients, 76% were White and 12% were African Americans. The majority of donors were White (69%), while African Americans composed 24% of the donor cohort. (Table 1a)

Race data was unavailable for 29 D-R pairs, leaving 134 D-R pairs with available race data. Race-concordant D-R pairs were 2x more common than race-discordant D-R pairs ($n = 93$ vs. 41). Similarly, sex-concordant D-R pairs were >2x more common than sex non-concordant D-R pairs ($n = 116$ vs. 45). D-R pairs were categorized as young donor – young recipient (28%), old donor – young recipient (24%), old donor – old recipient (29%), and young donor – old recipient (19%) (Table 1b).

Table 1a) Donor and recipient demographics: self-reported sex, self-reported race, and age at transplantation.

Demographics	Donor		Recipient	
	N	Percentage	N	Percentage
Self-Reported Sex				
F	66	40.49%	82	50.31%
M	9	58.28%	81	49.69%
Unknown	2	1.23%		
Self-Reported Race				
Black/African American	39	23.93%	20	12.27%
Asian	7	4.29%	5	3.07%
Unknown	5	3.07%	14	8.59%
White	112	68.71%	124	76.07%
Age at Tx.				
Mean	36.24		51.23	
Std Dev	13.88		15.06	

Table 1b) Total homoplasmic SNVs based on groups of donor-recipient race, sex, and age.

	N	Median	IQR	Range
Race				
Concordant	93	32	29 - 41	7 - 98
Nonconcordant	41	47	34 - 78	10 - 100
Sex				
Concordant	116	35	29 - 46	7 - 100
Nonconcordant	45	37	30 - 50	10 - 96
Age				
young donor - young recipient	44	36	27 - 45	10 - 100
old donor - young recipient	39	35	29 - 46	7 - 86
old donor - old recipient	47	35	29 - 53	7 - 98
young donor - old recipient	31	35	29 - 46	16 - 96

Characterization of SNVs

Stepwise depletion of nuclear DNA increased mtDNA over nuclear DNA ratio from 10-fold to greater than 10,000-fold. The 326 mtDNAs lung transplant samples (163 donor and 163 recipients) were sequenced to a mean depth of 9540x (Supplementary Table 2.1). We identified a median of 39 SNVs (Interquartile, IQR= 32 – 53) per D-R pair. The majority of the SNVs were homoplasmic with a median of 36 SNVs per D-R pair (IQR = 29 – 46). Heteroplasmic SNVs showed a median frequency of 3 SNVs per D-R pair, (IQR = 2 – 4). A third of all SNVs were in the D Loop (median = 13 SNVs , IQR= 10 – 17 SNVs), leaving two-third of SNVs located in the coding region of mtDNA (median = 27 SNVs, IQR = 21 – 37 SNVs). About a third of the latter SNVs (median = 6 SNVs , IQR = 4 – 9 SNVs) were nonsynonymous non-D-Loop SNVs and lead to proteins with different amino acid sequence between D-R (Table 2). After correcting for gene length, nonsynonymous SNVs were predominantly located in three mt gene regions: *MT-ND3* (0.56 ± 0.62 SNV per D-R, range: 0-3 SNVs per D-R), *MT-CYB* (1.67 ± 0.96 SNVs per D-R, range: 0-4 SNVs per D-R), and *MT-ATP6* (0.93 ± 0.82 SNVs per D-R, range: 0-3 SNVs per D-R). (Supplemental Table 2.2).

SNVs relationship with self-reported sex, age, and race

The number of SNVs, as well as nonsynonymous SNVs, were similar between sex-concordant and sex non-concordant D-R pairs (median = 11, IQR = 8 -13.75 vs. median 12, IQR = 9 – 14, $p = 0.396$, Figure 2a). Similarly, all four D-R age groups demonstrated similar amounts of nonsynonymous mtDNA. The young donor-old recipient group showed a trend towards higher number of nonsynonymous mtDNA SNVs compared to old donor-old recipient group, (median = 12 IQR = 11-14 vs median = 10, IQR = 8-14, $p = 0.067$); and to young donor-young recipient, (median = 10 SNVs, IQR = 7-13.75, $p = 0.077$, Figure 2b).

In contrast to the other two demographic variables, race concordant D-R pairs showed lower number of nonsynonymous SNVs when compared to the race non-concordant D-R pairs (median = 10; IQR = 8-13 vs. median = 12; IQR = 9.5-23, $p = 0.024$, Figure 2c).

Table 2. Median (IQR) number of SNVs for the entire lung transplant cohort. SNVs data for the whole mtDNA genome, without the DLoop region, nonsynonymous and without DLoop region, and nonsynonymous protein coding region are shown below. For all these specific regions we calculated the total, homoplasmic, and heteroplasmic SNVs respectively.

mtDNA SNVs (Lung Tx Cohort)	All		Homoplasmic		Heteroplasmic	
	Median	IQR	Median	IQR	Median	IQR
All SNVs	39	32 - 53	36	29 - 46	3	2 - 4
SNVs without DLoop	27	21 - 37	25	19 - 35	1	0 - 2
Nonsynonymous SNVs without DLoop	12	9 - 15	11	8 - 14	0	0 - 1
Nonsynonymous SNVs (Protein Coding Only)	6	4 - 9	6	4 - 8	0	0 - 1

Supplementary Table 2.1. Description of the number of mtDNA reads and mtDNA mapping rate for our sequencing results

	Mean (sd)
Raw Reads	5088401 (±5381323)
Mapping Rate	81% (± 7%)
Average Coverage	38532 (±35950)
Trimmed Mapped Reads (Removed Duplicate reads)	1667481.4 (±962395)

Supplementary Table 2.2. The average nonsynonymous number of SNVs in the lung transplant cohort per mitochondrial gene region.

Gene Symbol	Average SNVs	Standard Deviation	Minimum SNVs per DR pair	Maximum SNVs per DR pair	Gene Length	mt Genome	Normalized SNVs per gene length
MT-ATP6	0.90	0.81	0	3	681	16569	21.79
MT-ATP8	0.15	0.39	0	2	207	16569	11.79
MT-CO1	0.37	0.82	0	4	1542	16569	3.96
MT-CO2	0.22	0.43	0	2	684	16569	5.35
MT-CO3	0.23	0.45	0	2	784	16569	4.80
MT-CYB	1.55	0.93	0	4	1141	16569	22.45
MT-ND1	0.64	0.77	0	5	956	16569	11.06
MT-ND2	0.64	0.87	0	4	1042	16569	10.24
MT-ND3	0.55	0.61	0	3	346	16569	26.44
MT-ND4	0.17	0.40	0	2	1378	16569	1.99
MT-ND4L	0.02	0.15	0	1	297	16569	1.37
MT-ND5	1.04	1.34	0	6	1812	16569	9.54
MT-ND6	0.25	0.49	0	2	525	16569	7.94
MT-RNR1	1.36	1.37	0	6	954	16569	23.65
MT-RNR2	2.41	1.57	0	7	1559	16569	25.62
MT-TA	0.06	0.24	0	1	69	16569	14.73
MT-TC	0.04	0.20	0	1	66	16569	10.78
MT-TD	0.24	0.43	0	1	68	16569	58.30
MT-TE	0.03	0.17	0	1	69	16569	7.37
MT-TF	0.02	0.15	0	1	71	16569	5.73
MT-TG	0.06	0.24	0	1	68	16569	14.95
MT-TH	0.02	0.15	0	1	69	16569	5.89
MT-TI	0.01	0.11	0	1	69	16569	2.95
MT-TK	0.02	0.13	0	1	70	16569	4.36
MT-TL1	0.01	0.11	0	1	75	16569	2.71
MT-TL2	0.28	0.45	0	1	71	16569	64.43
MT-TM	0.04	0.20	0	1	68	16569	10.46
MT-TN	0.01	0.08	0	1	73	16569	1.39
MT-TP	0.01	0.08	0	1	68	16569	1.49
MT-TQ	0.08	0.27	0	1	72	16569	18.35
MT-TR	0.14	0.35	0	1	65	16569	35.97
MT-TS1	0.06	0.23	0	1	69	16569	13.26
MT-TS2	0.05	0.22	0	1	59	16569	13.78
MT-TT	0.38	0.56	0	2	66	16569	95.49
MT-TV	0.02	0.13	0	1	69	16569	4.42
MT-TW	0.03	0.17	0	1	68	16569	7.47

Note: These numbers are arbitrary units.

Figure 2a

Figure 2a. Number of nonsynonymous homoplasmic mtDNA SNVs based on donor-recipient concordant versus nonconcordant sex. The graph shows the number of nonsynonymous homoplasmic mtDNA SNVs for both concordant (grey) and nonconcordant (orange) D-R pairs. Median box plots are shown in red.

Figure 2b

Figure 2b. Number of nonsynonymous homoplasmic mtDNA SNVs based on donor-recipient age combinations.

We grouped the cohort based on the median age of the recipient and donor into young donor-young recipient, old donor-young recipient, old donor-old recipient, young donor-old recipient. The number of non synonymous homoplasmic mtDNA SNVs for each group is plotted. Groups were compared using Non-parametric Wilcoxon test Two p-values comparing groups are shown. Other p-values were >0.1

Figure 2c

Figure 2c. Number of nonsynonymous homoplasmic mtDNA SNVs based on concordant versus nonconcordant donor-recipient self-reported race. The graph shows the number of nonsynonymous homoplasmic mtDNA SNVs for both concordant (grey) and nonconcordant (orange) self-reported race D-R pairs. Median box plots are shown in red.

Allo-specific immunity from nonsynonymous SNVs

Donor-derived peptides demonstrated 26-fold higher IFN γ release compared to recipient-derived 20mer peptides, $p < 0.001$ (recipient-peptides: median spots number = 2.3, IQR(1.4 – 5.9); donor-peptides: median spots number=57.5, IQR(39.3 - 109.8); Figure 3). Individual IFN γ release plots for the 10 lung transplant subjects studied is displayed in Supplementary Figure 3.1. Moreover, IFN γ release was when comparing PBMCs collected at one-year post-transplant to PBMCs collected beyond one year after transplantation (Supplementary Figure 3.2).

Validation of the study in a Heart Transplant Cohort

To validate our findings, we sequenced the mtDNA for 19 heart transplant D-R pairs. SNVs were similar in the heart and lung transplant cohort. We identified a median of 48 SNVs (IQR= 38-80) per D-R pair. The majority of the SNVs were homoplasmic (median = 43 SNVs, IQR= 3-74), with few heteroplasmic SNVs (median = 3, IQR = 2-5). A third of all SNVs were in the D Loop (median = 15, IQR = 12-19), leaving two-third of SNVs located in the coding region of mtDNA (median = 33, IQR = 24-61). About a quarter of the latter SNVs (median = 8, IQR = 6-12) were nonsynonymous non-D-Loop SNVs and lead to proteins with different amino acids sequence between D-R (Table 3). Nonsynonymous SNVs were predominantly located in three mitochondrial gene regions: *MT-ND3* (0.63 ± 0.48 SNV per D-R, range: 0-3 SNVs per DR), *MT-CYB* (1.32 ± 0.97 SNVs per DR, range: 0-4 SNVs per DR), and *MT-ATP6* (1.16 ± 0.67 SNVs per DR, range: 0-3 SNVs per DR), (Supplementary Table 3.1).

Donor-derived peptides demonstrated 47-fold higher IFN γ release compared to recipient-derived 20mer peptides, $p < 0.001$ (recipient-peptides: median spots number=1.6, IQR(0.8 – 2.2); donor-peptides: median spots number=75.8, IQR(38.1 - 148.1); Figure 4). The individual IFN γ release spot number for each of the 4 heart transplant subjects studied is displayed in Supplementary Figure 4.1. Moreover, IFN γ release was similar when comparing PBMCs collected at one-year post-transplant to PBMCs collected beyond one year after transplantation (Supplementary Figure 4.2).

Figure 3

Figure 3. The median number of IFN γ spots for the lung transplant patients. The box plots represent the number of spots measured for each peptide: the orange box plot represent the measurements from the donor-derived peptides and the gray box plot represent the response measured from the recipient-derived peptides. For each individual spot the average of quadruplicate measurement was used. Each individual peptide's response is shown in the supplementary figure 1.

Supplementary Figure 3.1

Supplementary Figure 3.1. Number of spots measured in Elispot assays for each lung transplant patient. Histograms bars represent the number of spots measured for the donor-derived (gray) and recipient-derived (black) peptides in the Elispot assays. The black lines represent the standard deviation of quadruplicates.

Supplementary Figure 3.2.

Supplementary Figure 3.2. Number of spots measured in Elispot assays for each lung transplant patient at two different PBMC collection timepoints. Histograms bars represent the number of spots measured for the donor-derived (gray) and recipient-derived (black) peptides in the Elispot assays. The black lines represent the standard deviation of quadruplicates.

Table 3. Median (IQR) number of SNVs for the validation heart transplant cohort. SNVs data for the whole mtDNA genome, without the DLoop region, nonsynonymous and without DLoop region, and nonsynonymous protein coding region are shown below. For all these specific regions we calculated the total, homoplasmic, and heteroplasmic SNVs respectively.

mtDNA SNVs (Heart Tx Cohort)	All		Homoplasmic		Heteroplasmic	
	Median	IQR	Median	IQR	Median	IQR
All SNVs	48	38 - 80	43	33 - 74	3	2 - 5
SNVs without DLoop	33	24 - 61	30	21 - 57	1	0 - 2
Nonsynonymous SNVs without DLoop	12	9 - 22	11	9 - 22	0	0 - 1
Nonsynonymous SNVs (Protein Coding Only)	8	6 - 12	7	5 - 11	0	0 - 1

Supplementary Table 3.1. The average nonsynonymous number of SNVs in the heart transplant cohort per mitochondrial gene region.

Gene Symbol	Average SNVs	Standard Deviation	Minimum SNVs per DR pair	Maximum SNVs per DR pair	Gene Length	mt Genome	Normalized SNVs per gene length
MT-ATP6	1.16	0.67	0	2	681	16569	28.17
MT-ATP8	0.16	0.36	0	1	207	16569	12.64
MT-CO1	0.63	0.81	0	2	1542	16569	6.79
MT-CO2	0.21	0.41	0	1	684	16569	5.10
MT-CO3	0.26	0.44	0	1	784	16569	5.56
MT-CYB	1.32	0.98	0	3	1141	16569	19.11
MT-ND1	0.37	0.58	0	2	956	16569	6.39
MT-ND2	0.63	0.74	0	2	1042	16569	10.04
MT-ND3	0.63	0.48	0	1	346	16569	30.24
MT-ND4	0.32	0.57	0	2	1378	16569	3.80
MT-ND5	1.63	1.22	0	4	1812	16569	14.92
MT-ND6	0.26	0.55	0	2	525	16569	8.31
MT-RNR1	1.68	1.75	0	6	954	16569	29.25
MT-RNR2	2.74	1.77	0	7	1559	16569	29.09
MT-TA	0.16	0.36	0	1	69	16569	37.92
MT-TC	0.11	0.31	0	1	66	16569	26.43
MT-TD	0.32	0.46	0	1	68	16569	76.95
MT-TG	0.16	0.36	0	1	68	16569	38.47
MT-TI	0.11	0.31	0	1	69	16569	25.28
MT-TL1	0.11	0.31	0	1	75	16569	23.25
MT-TL2	0.16	0.36	0	1	71	16569	36.85
MT-TN	0.05	0.22	0	1	73	16569	11.95
MT-TP	0.05	0.22	0	1	68	16569	12.82
MT-TR	0.16	0.36	0	1	65	16569	40.25
MT-TS1	0.05	0.22	0	1	69	16569	12.64
MT-TS2	0.05	0.22	0	1	59	16569	14.78
MT-TT	0.47	0.68	0	2	66	16569	118.92
MT-TW	0.05	0.22	0	1	68	16569	12.82

Note: These numbers are arbitrary units. They do not represent SNVs.

Figure 4

Figure 4. The median number of IFN γ spots for the heart transplant patients. The box plots represent the number of spots measured for each peptide: the orange box plot represent the measurements from the donor-derived peptides and the gray box plot represent the response measured from the recipient-derived peptides. For each individual spot the average of quadruplicate measurement was used. Each individual peptide's response is shown in the supplementary figure 2.

Supplementary Figure 4.1

Supplementary Figure 4.1. Number of spots measured in Elispot assays for each heart transplant patient. Histograms bars represent the number of spots measured for the donor-derived (gray) and recipient-derived (black) peptides in the Elispot assays. The black lines represent the standard deviation of quadruplicates.

Supplementary Figure 4.2.

Supplementary Figure 4.2. Number of spots measured in Elispot assays for each heart transplant patient at two different PBMC collection timepoints. Histograms bars represent the number of spots measured for the donor-derived (gray) and recipient-derived (black) peptides in the Elispot assays. The black lines represent the standard deviation of quadruplicates.

Discussion

Release of mitochondrial content exposes transplant recipients to donor-derived proteins and mtDNA -- a very potent DAMP (33, 34). Scozzi and colleagues, as well as others (35), have described the association of circulating mtDNA with severe primary graft dysfunction after lung transplantation and proposed that the graft injury is coupled with neutrophil trafficking (36). We demonstrate that mtDNA peptide variants elicit allo-specific immune responses, which may potentially contribute to allograft rejection. In the absence of rejection, immune responses directed against the mitochondria may orchestrate deleterious effects on the allograft -- given the important cellular function of the mitochondrial, including apoptosis, metabolism, and immune regulation (15, 37). Additionally, cellular stress and necrosis, both common in solid-organ transplantation, promote extracellular mtDNA release (33, 38). Therefore, pharmacologically blocking the extracellular release of mitochondrial components could enhance immunosuppression, prevent allo-immunity, and potentially prevent rejection.

Cyclosporine A, and other drugs, inhibit the release of mitochondrial components through membrane pores(39-41). However, cyclosporine A and other calcineurin antagonists have been part of immunosuppression treatment for decades, but the blocking of mitochondrial membrane pores may not be sufficient to prevent mtDNA and DAMPs release. Other mechanisms of mitochondrial content release are more complex and involve binding of mt components to cellular cargo proteins (42, 43) or extracellular vesicles (44). Determining the ability of other drugs to target these more complex mechanisms would provide an additional avenue for immunosuppression.

In this study, we have shown that transplantation exposes patients to donor-derived SNVs outside the classical MHC region or other nuclear proteins. After transplantation, the donor-derived peptides triggered allo-specific immune responses, measured as IFN- γ release. These findings were consistent in heart and lung transplant patients, suggesting that donor-derived proteins trigger allo-specific immune responses across solid-organ transplant procedures. In addition, demographic factors that contribute to

mtDNA diversity, such as race, contributes to the number of SNVs. Race non-concordant D-R pairs demonstrated a higher number of SNVs compared to race-concordant D-R pairs. The implications of these findings are potentially broad and deserve further investigation.

Immunosuppressive therapies and post-transplant monitoring have reduced, but not eliminated, the incidence of acute rejection (1, 45). However, allo-specific immune responses directed to immunodominant antigens, such as HLA, do not explain all cases of rejection (4). Recently, several publications have implicated alloimmune responses directed to non-HLA antigens as causes of rejection. Our findings demonstrate that donor-derived mitochondrial proteins are immunogenic, even in a background of immunodominant HLA and non-HLA nuclear antigenic differences between donors and recipients. Considering the idea of personalized immunosuppression in donor-recipient pairs with low HLA mismatch at molecular level (46), our data suggest that the contribution of mtDNA SNVs, and possibly other known non-HLA factors, to the alloimmune response needs to be included in the personalized immunosuppression plans. The interaction of mitochondrial-directed alloimmune response and alloimmune response directed against immunodominant HLA deserves further investigation. Such investigations should also assess the role of mitochondrial allo-specific immune responses in transplant rejection.

The higher number of SNVs in race non-concordant transplant donor and recipient compared to race-concordant transplants may be associated with poorer outcomes. (10, 47-49). Greater HLA mismatch in race non-concordant transplants is a potential contributor (10, 50). Our work suggests that the higher number of mtDNA SNVs, in combination with genomic SNVs, in race non-concordant donor-recipient pairs may contribute to increased alloimmune responses and poorer outcomes.

Our study had several limitations that should be addressed in future studies. Our analyses focused on allo-specific mononuclear cell responses triggered by mitochondrial components and did not investigate

concurrent innate immune or antibody-immune responses. We also collected a limited amount of PBMCs, and as such only a subset of nonsynonymous SNVs identified per donor-recipient pair were tested with our Elispot assay. However, despite the small subset of nonsynonymous SNVs tested we observed a significant response over self in all patients tested. Characterization of immune responses directed against each SNV, as well as the cumulative effect of all SNVs for each patient, deserves further investigation. Lastly, we do not assess the relationship of mitochondrial-directed allo-specific immune responses to transplant outcomes such as acute rejection or long-term allograft survival. Our future studies will collect PBMCs at pre-specified time-points to enable such analyses.

In conclusion, we demonstrate that transplantation exposes patients to donor-derived mitochondrial SNVs and proteins. Some of these donor proteins have amino acid differences, compared to recipient proteins, that trigger allo-specific immune responses. The role of the observed allo-specific immune responses in transplant rejection, and the interaction of such immune responses with other known HLA and non-HLA directed responses deserves further investigation.

Disclosures

None of the authors had anything to disclose.

REFERENCES

1. Chambers DC, Yusen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khusch K, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. *J Heart Lung Transplant*. 2017;36(10):1047-59.
2. Opelz G, Collaborative Transplant S. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. *Lancet*. 2005;365(9470):1570-6.
3. Reindl-Schwaighofer R, Heinzl A, Kainz A, van Setten J, Jelencsics K, Hu K, et al. Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort. *Lancet*. 2019;393(10174):910-7.
4. Zhang Q, Reed EF. The importance of non-HLA antibodies in transplantation. *Nat Rev Nephrol*. 2016;12(8):484-95.

5. Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, et al. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. *Kidney Int.* 2019;96(1):189-201.
6. Deuse T, Wang D, Stubbendorff M, Itagaki R, Grabosch A, Greaves LC, et al. SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. *Cell Stem Cell.* 2015;16(1):33-8.
7. Duvvuri B, Duvvuri VR, Wang C, Chen L, Wagar LE, Jamnik V, et al. The human immune system recognizes neopeptides derived from mitochondrial DNA deletions. *J Immunol.* 2014;192(10):4581-91.
8. Cohen O, De La Zerda D, Beygui RE, Hekmat D, Laks H. Ethnicity as a predictor of graft longevity and recipient mortality in heart transplantation. *Transplant Proc.* 2007;39(10):3297-302.
9. Zhang Y. Impact of Donor Recipient Gender and Race Mismatch on Graft Outcomes in Patients With End-Stage Liver Disease Undergoing Liver Transplantation. *Prog Transplant.* 2017;27(1):39-47.
10. Morris AA, Kransdorf EP, Coleman BL, Colvin M. Racial and ethnic disparities in outcomes after heart transplantation: A systematic review of contributing factors and future directions to close the outcomes gap. *J Heart Lung Transplant.* 2016;35(8):953-61.
11. Lim WH, Chadban SJ, Clayton P, Budgeon CA, Murray K, Campbell SB, et al. Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients. *Clin Transplant.* 2012;26(4):E428-37.
12. Wallace DC, Chalkia D. Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. *Cold Spring Harbor perspectives in biology.* 2013;5(11):a021220.
13. Mesnard L, Muthukumar T, Burbach M, Li C, Shang H, Dadhania D, et al. Exome Sequencing and Prediction of Long-Term Kidney Allograft Function. *PLoS Comput Biol.* 2016;12(9):e1005088.
14. Pineda S, Sigdel TK, Chen J, Jackson AM, Sirota M, Sarwal MM. Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to Predict Antibody-Mediated Rejection Risk in Kidney Transplant. *Front Immunol.* 2017;8:1687.
15. West AP, Shadel GS. Mitochondrial DNA in innate immune responses and inflammatory pathology. *Nature reviews Immunology.* 2017;17(6):363-75.
16. Friedman JR, Nunnari J. Mitochondrial form and function. *Nature.* 2014;505(7483):335-43.
17. Gabaldon T, Huynen MA. Shaping the mitochondrial proteome. *Biochim Biophys Acta.* 2004;1659(2-3):212-20.
18. Weinberg SE, Sena LA, Chandel NS. Mitochondria in the regulation of innate and adaptive immunity. *Immunity.* 2015;42(3):406-17.
19. Shadel GS, Clayton DA. Mitochondrial DNA maintenance in vertebrates. *Annual review of biochemistry.* 1997;66:409-35.
20. Calvo SE, Mootha VK. The mitochondrial proteome and human disease. *Annual review of genomics and human genetics.* 2010;11:25-44.
21. Shadel GS, Horvath TL. Mitochondrial ROS signaling in organismal homeostasis. *Cell.* 2015;163(3):560-9.
22. Agbor-Enoh S, Jackson AM, Tunc I, Berry GJ, Cochrane A, Grimm D, et al. Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis. *J Heart Lung Transplant.* 2018;37(7):925-32.
23. De Vlaminck I, Martin L, Kertesz M, Patel K, Kowarsky M, Strehl C, et al. Noninvasive monitoring of infection and rejection after lung transplantation. *Proc Natl Acad Sci U S A.* 2015;112(43):13336-41.
24. Agbor-Enoh S, Fideli U, Doveikis J, Zhu J, Tunc I, Shah P, et al. Genomic Research Alliance for Transplantation (GRAfT): A Model for Long Term Transplant Studies in Thoracic Organ Transplantation. *The Journal of Heart and Lung Transplantation.* 2016;35(4):S161.

25. Deuse T, Hu X, Agbor-Enoh S, Koch M, Spitzer MH, Gravina A, et al. De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans. *Nat Biotechnol.* 2019.
26. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics.* 2014;30(15):2114-20.
27. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. *Nat Genet.* 1999;23(2):147.
28. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods.* 2012;9(4):357-9.
29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics.* 2009;25(16):2078-9.
30. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res.* 2012;22(3):568-76.
31. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010;38(16):e164.
32. The UniProt C. UniProt: the universal protein knowledgebase. *Nucleic Acids Res.* 2017;45(D1):D158-D69.
33. Nakahira K, Hisata S, Choi AM. The Roles of Mitochondrial Damage-Associated Molecular Patterns in Diseases. *Antioxid Redox Signal.* 2015;23(17):1329-50.
34. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. *Trends Immunol.* 2011;32(4):157-64.
35. Mallavia B, Liu F, Lefrancais E, Cleary SJ, Kwaan N, Tian JJ, et al. Mitochondrial DNA Stimulates TLR9-Dependent NET Formation in Primary Graft Dysfunction. *Am J Respir Cell Mol Biol.* 2019.
36. Scozzi D, Ibrahim M, Liao FY, Lin X, Hsiao HM, Hachem R, et al. Mitochondrial damage-associated molecular patterns released by lung transplants are associated with primary graft dysfunction. *Am J Transplant.* 2019;19(5):1464-77.
37. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. *Cell.* 2012;148(6):1145-59.
38. Zhang Q, Itagaki K, Hauser CJ. Mitochondrial DNA Is Released by Shock and Activates Neutrophils Via P38 Map Kinase. *Shock.* 2010;34(1):55-9.
39. Patrushev M, Kasymov V, Patrusheva V, Ushakova T, Gogvadze V, Gaziev A. Mitochondrial permeability transition triggers the release of mtDNA fragments. *Cell Mol Life Sci.* 2004;61(24):3100-3.
40. Boyapati RK, Tamborska A, Dorward DA, Ho GT. Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases. *F1000Res.* 2017;6:169.
41. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nat Immunol.* 2011;12(3):222-30.
42. Neuspiel M, Schauss AC, Braschi E, Zunino R, Rippstein P, Rachubinski RA, et al. Cargo-selected transport from the mitochondria to peroxisomes is mediated by vesicular carriers. *Curr Biol.* 2008;18(2):102-8.
43. Soubannier V, Rippstein P, Kaufman BA, Shoubridge EA, McBride HM. Reconstitution of mitochondria derived vesicle formation demonstrates selective enrichment of oxidized cargo. *PLoS One.* 2012;7(12):e52830.
44. Guescini M, Guidolin D, Vallorani L, Casadei L, Gioacchini AM, Tibollo P, et al. C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction. *Exp Cell Res.* 2010;316(12):1977-84.

45. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. *J Heart Lung Transplant*. 2017;36(10):1037-46.
46. Wiebe C, Ho J, Gibson IW, Rush DN, Nickerson PW. Carpe diem-Time to transition from empiric to precision medicine in kidney transplantation. *Am J Transplant*. 2018;18(7):1615-25.
47. Allen JG, Weiss ES, Merlo CA, Baumgartner WA, Conte JV, Shah AS. Impact of donor-recipient race matching on survival after lung transplantation: analysis of over 11,000 patients. *J Heart Lung Transplant*. 2009;28(10):1063-71.
48. Peled Y, Loewenthal R, Kassif Y, Raichlin E, Younis A, Younis A, et al. Donor-recipient ethnic mismatching impacts short- and long-term results of heart transplantation. *Clin Transplant*. 2018;32(10):e13389.
49. Morris AA, Cole RT, Veledar E, Bellam N, Laskar SR, Smith AL, et al. Influence of race/ethnic differences in pre-transplantation panel reactive antibody on outcomes in heart transplant recipients. *J Am Coll Cardiol*. 2013;62(24):2308-15.
50. Askar M, Chan M, McCurry K, Budev M, Schold J. HLA Mismatches Is an Independent Risk Factor for Worse Patient Survival among Lung Transplant Recipients in the United States. *J Heart Lung Transpl*. 2014;33(4):S188-S9.